Femasys Inc. (NASDAQ:FEMY – Get Free Report) CFO Dov Elefant acquired 15,625 shares of the company’s stock in a transaction dated Friday, August 7th. The stock was acquired at an average price of $3.20 per share, for a total transaction of $50,000.00. Following the completion of the purchase, the chief financial officer directly owned 15,625 shares of the company’s stock, valued at $50,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Femasys Stock Performance
Shares of FEMY stock opened at $2.35 on Thursday. The company has a current ratio of 3.91, a quick ratio of 1.98 and a debt-to-equity ratio of 0.53. Femasys Inc. has a 1 year low of $2.19 and a 1 year high of $22.20. The firm’s fifty day simple moving average is $3.77 and its 200 day simple moving average is $7.42. The firm has a market capitalization of $7.10 million, a P/E ratio of -0.44 and a beta of -2.08.
Hedge Funds Weigh In On Femasys
Institutional investors have recently modified their holdings of the stock. Banco BTG Pactual S.A. bought a new stake in shares of Femasys in the 4th quarter valued at $88,000. Geode Capital Management LLC lifted its holdings in Femasys by 50.8% during the fourth quarter. Geode Capital Management LLC now owns 389,280 shares of the company’s stock worth $224,000 after acquiring an additional 131,052 shares in the last quarter. Jane Street Group LLC acquired a new position in Femasys in the fourth quarter valued at about $62,000. Cetera Investment Advisers acquired a new position in Femasys in the fourth quarter valued at about $36,000. Finally, HRT Financial LP bought a new stake in shares of Femasys in the fourth quarter worth about $30,000. 65.27% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Check Out Our Latest Research Report on Femasys
Femasys News Roundup
Here are the key news stories impacting Femasys this week:
- Positive Sentiment: Femasys secured new U.S. and international patents covering FemBloc’s blended polymer, complementing existing delivery-system patents. The broader protection across the U.S., Europe, Japan, South Korea, Brazil, India and other markets could strengthen FemBloc’s competitive position and support future licensing or commercialization partnerships. FemBloc is already approved in Europe, the U.K. and New Zealand, although it remains investigational in the United States. Femasys Strengthens and Extends Global Patent Protection for FemBloc
- Positive Sentiment: Multiple company insiders purchased shares at $3.20, including the CEO, CFO, COO, CTO and Chief Medical Affairs executive. The purchases, totaling approximately $134,000, may be viewed as a vote of confidence by management, though the transactions are relatively small compared with the company’s potential capital needs. Femasys Insider Buying
- Neutral Sentiment: Femasys recently announced a $30 million private placement. The financing should provide substantial funds for operations and the ongoing FINALE pivotal trial, but investors need to assess the security terms and potential dilution before determining its net impact on existing shareholders. Femasys Completes $30 Million Private Placement Financing
- Negative Sentiment: FemBloc still requires successful completion of its U.S. pivotal trial and FDA approval. The company continues to face significant clinical, regulatory and commercialization risks, while Femasys remains unprofitable. Shares are trading well below their 50-day and 200-day moving averages, reflecting persistent investor caution.
About Femasys
Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.
The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.
Featured Articles
- Five stocks we like better than Femasys
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.
